Lupin Result beats expectations; Near term revenue drivers improves grows visibility

Transcription

1 Result beats expectations; Near term revenue drivers improves grows visibility February 10, 2017 Surajit Pal Rating Accumulate Price Rs1,495 Target Price Rs1,730 Implied Upside 15.7% Sensex 28,330 Nifty 8,778 (Prices as on February 09, 2017) Trading data Market Cap. (Rs bn) Shares o/s (m) M Avg. Daily value (Rs m) Major shareholders Promoters 46.71% Foreign 33.27% Domestic Inst. 8.03% Public & Other 11.99% Stock Performance (%) 1M 6M 12M Absolute 0.3 (7.0) (21.5) Relative (5.7) (7.9) (39.4) How we differ from Consensus EPS (Rs) PL Cons. % Diff Price Performance (RIC: LUPN.BO, BB: LPC IN) Overall beat on better show in US and ROW markets: Lupin s sales, adj. EBITDA and PAT grew by 31%, 75% and 21% yoy respectively vs our estimates of 22%, 34% and 14%.. Lupin revenue growth from US and ROW markets were 58% and 22% YoY respectively. Glumetza was major driver in US market and Branded business drove ROW market growth in. With better control over opex,, Lupin s gross margin and adj. EBITDA margin grew by 400bps and 640bps respectively. R&D costs though were at Rs5.7bn, 13% of sales in, as guided. US sales increased up 9% QoQ: Despite competition in older generics and growing competition in Fortamet (due to launch of Mylan generic), Lupin s US sales grew due to 1)better Glumetza sales, 2)new launches from own and Gavis portfolio, 3)seasonal benefits in Cephalosporin molecules and 4)sales of branded drugs including Methergin and Antara. Branded sales were US$22m in vs US$18m in. Japan sale to be driven by Shinogi deal: With products buyout of Shinogi, management expects foray into CNS market and see a significant increase in market share to become the 7 th largest in generics. Sales growth of 20% YoY in was driven by existing brands and expansion in hospital segment. Valuation Maintain Accumulate, increase TP to Rs1,730: India formulations grew 12% despite headwinds on account of the impact due to demonetisation. Lupin expects 15% growth in FY18E despite expected sales possible disruption/adjustments due to GST implementation. Management guided for key US launches including Minastrin, Epzicom, Vigamox and Namenda XR in FY18E along with few more controlled substance drugs from Gavis portfolio. With better cost management and visibility of near term growth drivers, the stock is expected to be rerated. We roll over our earnings estimates to FY19E and our 12 months TP is increased to Rs1,730 (earlier Rs1650) at a target PER of 22.4x Sep 18 earnings. We maintain Accumulate. Key financials (Y/e March) E 2019E Revenues (Rs m) 137, , , ,621 Growth (%) EBITDA (Rs m) 32,466 44,848 51,187 58,812 PAT (Rs m) 22,707 27,976 32,334 37,113 EPS (Rs) Growth (%) (5.7) Net DPS (Rs) Result Update (Rs) 2,500 1, Feb16 Apr16 Jun16 Aug16 Oct16 Dec16 Feb17 Profitability & Valuation E 2019E EBITDA margin (%) RoE (%) RoCE (%) EV / sales (x) EV / EBITDA (x) PE (x) P / BV (x) Net dividend yield (%) Source: Bloomberg Source: Company Data; PL Research Prabhudas Lilladher Pvt. Ltd. and/or its associates (the 'Firm') does and/or seeks to do business with companies covered in its research reports. As a result investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of the report. Investors should consider this report as only a single factor in making their investment decision. Please refer to important disclosures and disclaimers at the end of the report

2 Key takeaways from Conference call US sales increased 9% QoQ on the back of increased market share in Glumetza and new launches in. Going forward, management expects competition in Glumetza from Valeant AG as well as generics from Sun Pharma and Teva in next 12 months The management guided for 810% value erosion in older generics other than top5 products in US. We expect sales of Glumetza and Fortamet contributed 4050% of US portfolio in. Lupin s branded generics sales were US$22m, including major contribution from Methergine (brand of Gavis) followed by Antara and Suprax in. Management guided for approvals in Welchol, Renvela/Renagel and Remicade in Q1FY19E. It expects to launch one FTF (Minastrin) and Epzicom & Namenda XR in FY18E. Management expects 45 approvals each from Goa and Somerset plants and few approvals from Indore facility in FY18E. R&D expenses were at 13% in and we expect it to be maintained above 12.5% as clinical trials for AdvairMDI and DPI, Specialty drugs to continue in FY17E19E Lupin reduced its guidance of Gavis Pharma sales to US$250m in FY18E as they expect a delay in the launch by 6 months. It expects Methergine brand to be large enough to match peak revenues of Suprax (i.e US$100m) Domestic formulations growth guidance was maintained at 15% with high risk of impact from the ban of combination drugs by regulator and GST impact. Currently, NLEM drugs contribute 23% of domestic portfolio. Management has also guided for inlicense drug Linagliptin to achieve revenues of Rs1bn in three years from the date of launch in November 2015 Japan generic business is guided to grow in double digits in Q4FY17E on the back of better performance in I rom Pharma and acquisition of 21 products from Shinogi Management has guided for capex of Rs19bn in FY17E which is expected to reduce to Rs1314bn in FY18E. February 10,

3 Exhibit 1: Result Overview (Rs m) Y/e March YoY gr. (%) 9MFY17 9MFY16 YoY gr. (%) Net Sales 44,049 33, ,112 1,29,579 96, Raw Material 13,016 11, ,429 38,164 32, % of Net Sales Personnel Cost 7,312 5, ,124 21,494 15, % of Net Sales Others 12,343 10, ,072 36,665 29, % of Net Sales Total Expenditure 32,670 27, ,624 96,323 77, EBITDA 11,379 6, ,487 33,256 19, Margin (%) Depreciation 2,309 1, ,112 6,448 3, EBIT 9,070 5, ,376 26,808 16, Other Income 1,815 2,637 (31.2) 1,064 4,396 5,940 (26.0) Interest , PBT 10,426 7, ,177 30,162 21, ExtraOrd. Inc./Exps. (0) 8 (34) (29) 10 Total Taxes 4,095 2, ,589 8,418 6, ETR (%) Reported PAT 6,331 5, ,622 21,773 15, Other Comprehensive Income (1,353) (572) 179 (262) (2,193) Total Comprehensive Income 4,978 4, ,801 21,510 12, February 10,

4 Exhibit 2: Major Sources of Revenues (Rs m) Y/e March YoY gr. (%) 9MFY17 9MFY16 YoY gr. (%) Domestic market 9,912 8, ,958 29,369 26, % of Sales International market (Exports) 34,157 24, ,154 1,00,230 69, % of Sales Total 44,069 33, ,112 1,29,599 96, Formulations 41,385 30, ,193 1,21,030 86, % of Sales India 9,912 8, ,958 29,369 26, % of Sales International market (Exports) 31,473 21, ,235 91,661 60, % of Sales North America 21,775 13, ,978 63,639 37, % of Sales Europe, Middle East, Africa (EMEA) 2,555 2, ,355 7,104 6,224 % of Sales Emerging Markets (ROW) & LATAM 1,542 1, ,382 4,381 3, % of Sales APAC 5,601 4, ,520 16,537 13,172 % of Sales NonJapan 1, ,152 3,445 2,968 Japan 4,492 3, ,368 13,092 10, % of Sales APIs 2,684 2,835 (5.3) 2,919 8,569 9,440 (9.2) % of Sales Grand Total 44,069 33, ,112 1,29,599 96, February 10,

5 Exhibit 3: India formulation sales and growth: Acute makes pain in growth Sales (Rs m) YoY gr. (RHS) (%) 1 10,000 8,000 6,000 4, () Exhibit 4: US generic sales (US$ m): Current products facing strong pricing pressure Rev. (US $ m) Average Rev (US$m) Exhibit 5: Emerging market sales: Acquisitions help in incorporating sales growth 3,500 3,000 2,500 (Rs m) 1, February 10,

6 Exhibit 6: Japan generic sales, growth: Continue to be rickety on new price cut schedule 5,000 4,000 3,000 Sales (Rs m) YoY gr. (RHS) (%) () Exhibit 7: API sales and growth: Average performer 3,500 3,000 2,500 1, Sales (Rs m) YoY gr. (RHS) (%) 30.0 () () (30.0) Exhibit 8: Sales and sales growth: Overall disappointing, unable to make headway in key geographies 50,000 40,000 30,000 20,000 10,000 Sales (Rs m) YoY gr. (RHS) (%) () February 10,

7 Exhibit 9: EBITDA and Margin: Strong price impact in top5 US generics reduces margin 14, ,000 8,000 6,000 4,000 EBITDA (Rs m) Margin % (RHS) Exhibit 10: R&D Exps as % of sales: Guided to be % in FY16E, FY17E 7,000 6,000 5,000 4,000 3,000 Expenses (Rs m) Margin (%) (RHS) February 10,

8 Income Statement (Rs m) Net Revenue 137, , , ,621 Raw Material Expenses 43,094 52,670 57,198 63,145 Gross Profit 93, , , ,476 Employee Cost 21,077 28,682 31,604 34,659 Other Expenses 40,379 47,629 53,902 60,004 EBITDA 32,466 44,848 51,187 58,812 Depr. & Amortization 4,635 8,807 9,247 10,172 Net Interest 446 1,582 1,642 1,810 Other Income 6,946 5,557 5,946 6,243 Profit before Tax 34,330 40,016 46,245 53,074 Total Tax 11,536 12,005 13,873 15,922 Profit after Tax 22,795 28,011 32,371 37,152 ExOd items / Min. Int Adj. PAT 22,707 27,976 32,334 37,113 Avg. Shares O/S (m) EPS (Rs.) Cash Flow Abstract (Rs m) C/F from Operations (3,690) 11,676 16,116 15,274 C/F from Investing (69,434) (22,101) (14,231) (15,383) C/F from Financing 60,055 10,212 5,664 8,143 Inc. / Dec. in Cash (13,069) (213) 7,549 8,035 Opening Cash 21,084 8,379 8,166 15,715 Closing Cash 8,015 8,166 15,715 23,749 FCFF (22,791) (3,220) 11,992 12,955 FCFE 43,613 4,790 21,721 24,882 Key Financial Metrics Growth Revenue (%) EBITDA (%) (5.9) PAT (%) (5.5) EPS (%) (5.7) Profitability EBITDA Margin (%) PAT Margin (%) RoCE (%) RoE (%) Balance Sheet Net Debt : Equity Net Wrkng Cap. (days) Valuation PER (x) P / B (x) EV / EBITDA (x) EV / Sales (x) Earnings Quality Eff. Tax Rate Other Inc / PBT Eff. Depr. Rate (%) FCFE / PAT Balance Sheet Abstract (Rs m) Shareholder's Funds 109, , , ,941 Total Debt 71,775 79,785 89, ,441 Other Liabilities 6,922 6,182 5,593 5,128 Total Liabilities 188, , , ,510 Net Fixed Assets 86,379 82,486 87,470 92,681 Goodwill 29,644 42,984 49,431 56,846 Investments Net Current Assets 61,954 79, , ,020 Cash & Equivalents 8,379 8,166 15,715 23,749 Other Current Assets 89, , , ,348 Current Liabilities 35,836 41,993 40,879 41,077 Other Assets 10,509 13,134 17,719 23,908 Total Assets 188, , , ,510 Quarterly Financials (Rs m) Y/e March Net Revenue 40,913 43,136 42,112 44,049 EBITDA 12,256 11,822 9,487 11,379 % of revenue Depr. & Amortization 1,487 2,027 2,112 2,309 Net Interest Other Income 1,233 2,085 1,064 1,815 Profit before Tax 11,789 11,560 8,177 10,426 Total Tax 4,188 2,734 1,589 4,095 Profit after Tax 7,569 8,819 6,622 6,331 Adj. PAT 7,569 8,819 6,801 4,978 Key Operating Metrics (Rs m) India Formulations 33,916 39,843 45,421 52,234 North America 63,685 89,972 99, ,888 APAC 13,646 17,651 20,065 23,006 ROW Formulations & LATAM 13,695 16,054 18,901 22,055 APIs 12,074 11,147 11,309 11,535. February 10,

9 Prabhudas Lilladher Pvt. Ltd. 3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai , India Tel: (91 22) Fax: (91 22) Rating Distribution of Research Coverage PL s Recommendation Nomenclature % of Total Coverage 60% 50% 40% 30% 20% 10% 0% 50.9% 32.8% 16.4% 0.0% BUY Accumulate Reduce Sell BUY : Over 15% Outperformance to Sensex over 12months Accumulate : Outperformance to Sensex over 12months Reduce : Underperformance to Sensex over 12months Sell : Over 15% underperformance to Sensex over 12months Trading Buy : Over 10% absolute upside in 1month Trading Sell : Over 10% absolute decline in 1month Not Rated (NR) : No specific call on the stock Under Review (UR) : Rating likely to change shortly DISCLAIMER/DISCLOSURES ANALYST CERTIFICATION We/I, Mr. Surajit Pal (PGDBA, CFA, M.Com), Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Terms & conditions and other disclosures: Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as PL ) is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security. The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein. Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor. Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication. PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document. PL is in the process of applying for certificate of registration as Research Analyst under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities. PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company. PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report. PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report. PL or its associates might have received compensation from the subject company in the past twelve months. PL or its associates might have managed or comanaged public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months. PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months. PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report. PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report. It is confirmed that Mr. Surajit Pal (PGDBA, CFA, M.Com), Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report. The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all o the foregoing, among other things, may give rise to real or potential conflicts of interest. PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. DISCLAIMER/DISCLOSURES (FOR US CLIENTS) ANALYST CERTIFICATION The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report Terms & conditions and other disclosures: This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated brokerdealer and therefore the analyst(s) is/are not subject to supervision by a U.S. brokerdealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered brokerdealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer. February 10,